Stocklytics Platform
Asset logo for symbol RNA
Avidity Biosciences
RNA60
$45.67arrow_drop_down3.44%-$1.63
Asset logo for symbol RNA
RNA60

$45.67

arrow_drop_down3.44%

Income Statement (RNA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$82.62M-$77.18M-$66.74M-$59.35M-$52.63M
EBITDA-$81.93M-$76.54M-$66.12M-$58.05M-$52.10M
gross Profit$1.35M$2.90M$1.57M$1.51M$1.05M
NET Income-$70.79M-$68.85M-$60.44M-$52.35M-$47.02M
total Revenue$2.04M$3.54M$2.19M$2.81M$2.31M

Balance Sheet (RNA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$567.36M-$462.25M-$175.23M-$75.06M-$144.36M
stockholders Equity$1.22B$830.89M$500.76M$517.46M$559.17M
total Assets$1.34B$951.47M$628.55M$573.16M$610.78M
total Debt$8.38M$9.14M$9.85M$10.58M$9.51M
total Liabilities$126.38M$120.57M$127.79M$55.69M$51.60M

Cash Flow (RNA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$446.72M$389.44M$31.89M$40.00K$38.97M
free Cash Flow-$65.53M-$71.29M$15.63M-$37.71M-$50.42M
investing Cash Flow----$46.04M
operating Cash Flow-$65.00M-$70.38M$16.50M-$36.79M-$49.80M

Avidity Biosciences (RNA) Financials

Avidity Biosciences Inc (RNA) is a biotechnology company that specializes in the development of RNA-based therapeutics. The company's financial performance can be assessed through its income statement, which provides a snapshot of its revenues and expenses. The income statement shows the total revenue generated by Avidity Biosciences Inc (RNA), which reflects the amount of money earned from the sale of its products or services. It also highlights the gross profit, which is the revenue minus the cost of goods sold. Additionally, the income statement includes the net income from stockholders, which represents the profit or loss after deducting all expenses and taxes.
Another important financial metric is the EBIT (Earnings Before Interest and Taxes), which measures the company's operating profit before deducting interest and taxes. This metric provides insights into Avidity Biosciences Inc (RNA)'s ability to generate profit from its core operations. Similarly, the EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of operating performance that excludes non-cash expenses. It provides a clearer picture of the company's operating efficiency by removing the effects of depreciation and amortization.
Moving on to the balance sheet, it provides a snapshot of Avidity Biosciences Inc (RNA)'s financial position at a specific point in time. It includes the company's total assets, which represent the value of all its resources, such as cash, inventory, and property. The total liabilities represent the company's debts and obligations, including both short-term and long-term liabilities. The stockholders' equity represents the residual value of the company's assets after deducting its liabilities. It is an important measure of Avidity Biosciences Inc (RNA)'s financial health as it indicates the amount of capital contributed by shareholders.
Furthermore, the balance sheet includes the cash equivalents, which are highly liquid investments that can be readily converted into cash. These investments help Avidity Biosciences Inc (RNA) maintain its liquidity and meet its short-term financial obligations. The net debt is a measure of the company's overall debt, which includes both short-term and long-term debt, minus its cash and cash equivalents. It shows whether the company is in a strong financial position to meet its obligations or if it is heavily indebted.
Finally, the cash flow statement provides insights into Avidity Biosciences Inc (RNA)'s cash inflows and outflows. It includes the operating cash flow, which shows the amount of cash generated or used by the company's core operations. The investing cash flow reflects the cash flows associated with the company's investment activities, such as the purchase or sale of property, plant, and equipment. The financing cash flow represents the cash flows related to the company's financing activities, such as the issuance or repayment of debt. Lastly, the cash flow statement includes the free cash flow, which is the cash left over after deducting capital expenditures from operating cash flow. This measure indicates the company's ability to generate cash for growth or to return to shareholders.
add Avidity Biosciences  to watchlist

Keep an eye on Avidity Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media